Polymyalgia Rheumatica Development in a Patient Under PI3K Inhibitor Therapy for Chronic Lymphocytic Leukaemia
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
We report a patient with chronic lymphocytic leukaemia (CLL) who was treated with idelalisib, a PI3Kδ inhibitor with rituximab. After 20 weeks of treatment, the patient developed classical signs and symptoms of polymyalgia rheumatica (PMR) in association with an elevated C reactive protein of 74 mg/L. After 2 weeks of prednisolone 15 mg daily symptoms had resolved and acute phase markers normalised. To our knowledge, this is the first report of PMR developing as a complication of PI3Kδ inhibitor treatment of CLL.
References
1.
Banerjee S, Brosnahan G
. Polymyalgia rheumatica in a renal transplant patient. J Ark Med Soc. 2008; 105(5):115-7.
View
2.
Macchioni P, Boiardi L, Catanoso M, Pulsatelli L, Pipitone N, Meliconi R
. Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature. Semin Arthritis Rheum. 2013; 43(1):113-8.
DOI: 10.1016/j.semarthrit.2013.01.003.
View
3.
Bhatia A, Ell P, Edwards J
. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis. 2005; 64(7):1099-100.
PMC: 1755553.
DOI: 10.1136/ard.2005.036533.
View
4.
Curran M, Montalvo W, Yagita H, Allison J
. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010; 107(9):4275-80.
PMC: 2840093.
DOI: 10.1073/pnas.0915174107.
View
5.
Oke A, Sammut L, Hull R
. Comment on: Musculoskeletal complication of haematological disease. Rheumatology (Oxford). 2016; 56(2):320-321.
DOI: 10.1093/rheumatology/kew372.
View